Lista de obras - Tanya Applegate - Dominio Público Uruguay

96 shRNAs designed for maximal coverage of HIV-1 variants

artículo científico publicado en 2009

A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals

artículo científico publicado en 2014

A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies

artículo científico publicado en 2016

A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells

artículo científico publicado en 2014

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

artículo científico publicado en 2017

Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection

artículo científico publicado en 2016

An infinitely expandable cloning strategy plus repeat-proof PCR for working with multiple shRNA.

artículo científico publicado en 2008

Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.

artículo científico publicado en 2016

Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success

artículo científico publicado en 2009

Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach

artículo científico publicado en 2017

Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment.

scientific article published on 31 January 2017

Dynamics of HCV RNA levels during acute hepatitis C virus infection

artículo científico publicado en 2014

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

artículo científico publicado en 2017

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial

artículo científico publicado en 2020

Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples

scientific article published on 26 June 2018

Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study

scientific article published on 18 September 2019

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study

artículo científico publicado en 2017

Evaluation of the Xpert® HCV Viral Load Fingerstick point-of-care assay

artículo científico publicado en 2018

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study

artículo científico publicado en 2015

Factors that influence deoxyribozyme cleavage during polymerase chain reaction

artículo científico publicado en 2000

HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype

artículo científico publicado en 2017

HCV reinfection incidence among individuals treated for recent infection.

artículo científico publicado en 2017

HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.

artículo científico publicado en 2015

HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection

artículo científico publicado en 2016

Hepatitis C Virus Diagnosis and the Holy Grail

artículo científico publicado en 2018

Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis

artículo científico publicado en 2017

Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse

artículo científico publicado en 2017

Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia

artículo científico publicado en 2016

In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy

artículo científico publicado en 2010

Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study

artículo científico publicado en 2014

Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.

artículo científico publicado en 2015

Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection

artículo científico publicado en 2017

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection

artículo científico publicado en 2016

Metabolism of ethanol by rat pancreatic acinar cells

artículo científico publicado en 1998

Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada

artículo científico publicado en 2015

Mixed HCV infection and reinfection in people who inject drugs--impact on therapy

artículo científico

Multiple shRNA combinations for near-complete coverage of all HIV-1 strains

artículo científico publicado en 2011

Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.

artículo científico publicado en 2014

Non-oxidative metabolism of ethanol by rat pancreatic acini.

artículo científico publicado en 2004

Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study

artículo científico publicado en 2015

Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture.

artículo científico publicado en 1998

Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.

artículo científico publicado en 2016

Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada

artículo científico publicado en 2014

Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.

artículo científico publicado en 2013

Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection

artículo científico publicado en 2013

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

artículo científico publicado en 2010

Sequencing of the Hepatitis C Virus: A Systematic Review.

artículo científico publicado en 2013

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies

artículo científico publicado en 2016

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.

artículo científico publicado en 2016

Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.

artículo científico publicado en 2018

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study

artículo científico publicado en 2016

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

artículo científico publicado en 2018

The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis

artículo científico publicado en 2015

The effect of ethanol on pancreatic enzymes--a dietary artefact?

artículo científico publicado en 1998

Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells

artículo científico publicado en 2009

Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada

artículo científico publicado en 2016

Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.

artículo científico publicado en 2016

Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection

artículo científico publicado en 2012

Lista de obras de Tanya Applegate

96 shRNAs designed for maximal coverage of HIV-1 variants

A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals

A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies

A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection

An infinitely expandable cloning strategy plus repeat-proof PCR for working with multiple shRNA.

Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.

Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success

Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach

Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment.

Dynamics of HCV RNA levels during acute hepatitis C virus infection

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial

Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples

Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study

Evaluation of the Xpert® HCV Viral Load Fingerstick point-of-care assay

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study

Factors that influence deoxyribozyme cleavage during polymerase chain reaction

HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype

HCV reinfection incidence among individuals treated for recent infection.

HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.

HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection

Hepatitis C Virus Diagnosis and the Holy Grail

Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis

Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse

Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia

In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy

Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study

Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.

Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection

Metabolism of ethanol by rat pancreatic acinar cells

Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada

Mixed HCV infection and reinfection in people who inject drugs--impact on therapy

Multiple shRNA combinations for near-complete coverage of all HIV-1 strains

Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.

Non-oxidative metabolism of ethanol by rat pancreatic acini.

Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study

Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture.

Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.

Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada

Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.

Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

Sequencing of the Hepatitis C Virus: A Systematic Review.

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.

Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis

The effect of ethanol on pancreatic enzymes--a dietary artefact?

Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells

Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada

Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.

Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection